Pompe Disease: The Missing Enzyme, and the Replacement That Changed the Story

Last updated September 4, 2026.

Pompe disease is a rare inherited condition in which the body lacks a working copy of an enzyme called acid alpha-glucosidase, whose job is to break down stored glycogen inside cells. Without it, glycogen accumulates, and the tissues that suffer most are the muscles: the heart, the limbs, and the muscles of breathing. It comes in two main forms, a severe infant form and a slower form appearing any time from childhood to adulthood, and both have been transformed by a replacement enzyme given by infusion.

The two forms

The infant form arrives in the first months: a floppy baby with poor feeding, a big weakened heart, and breathing trouble. Untreated it is devastating, and enzyme treatment started early has rewritten its outcomes. The later form is a different, slower story: weakness creeping over years, in hips, shoulders, back, and the breathing muscles, often mistaken for muscular dystrophy or ordinary unfitness for a long time before diagnosis. Heart involvement is usually mild in this form; breathing is the system to watch.

Late-onset Pompe found on newborn screening is a diagnosis years ahead of its symptoms, and that head start is the advantage: monitored growth, enzyme treatment when the time is right, and a field that keeps improving.

Start a free AI doctor consult →

How it is diagnosed and inherited

A blood test measuring the enzyme activity confirms it, with genetic testing to follow. Many newborns are now found through screening programs before any symptoms. The inheritance is recessive: both parents carry one silent copy, each child of two carriers has a one in four chance of the condition, and carriers themselves are healthy. Siblings of a diagnosed child should be tested, and genetic counseling helps the whole family map it.

How it is treated

The centerpiece is enzyme replacement therapy: the missing enzyme, made in a lab, infused through a vein every two weeks. In babies it must start early, and it has turned a once uniformly fatal diagnosis into a condition many children grow through, attending school and building lives. In the later form, it slows or stabilizes the weakness for most people, and starting before the damage is advanced preserves the most. Around the enzyme sits the scaffolding: breathing checks with breathing support at night when needed, physiotherapy to keep muscles working, feeding support for babies and for adults who lose weight, and heart monitoring. The infusions are lifelong, the schedule becomes routine, and the evidence keeps moving: newer enzyme versions and gene therapies are in trials, which matters to families planning decades ahead.

Early enzyme treatment is the whole ballgame. In the infant form, weeks matter; in the later form, starting before major weakness preserves the most function. If treatment is offered, treat the start date as urgent.
Watch the breathing, not just the limbs. The breathing muscles weaken quietly, sometimes before walking is affected. Night-time symptoms, morning headaches, and unrefreshing sleep deserve reporting.
Get the family tested and counseled. Siblings of a diagnosed child each carry a one in four risk, and future pregnancies can be tested. Genetic counseling turns a frightening inheritance pattern into a map.

If you are weighing the risks and benefits of any medicine mentioned here, our overview of how medicines are tested and monitored for safety explains what those conversations are built on.

What a Pymander AI doctor consult looks like

Our newborn daughter has just been picked up by the newborn screening program with Pompe disease, the late-onset type they think. She is two weeks old and looks perfectly healthy. They are talking about enzyme infusions eventually and watching her. How can she be fine and have this at the same time? What does her future actually look like?

She can be fine and have it because late-onset Pompe is exactly that: a condition written into her cells that will take years, sometimes many years, to show. The glycogen builds slowly, and a two-week-old with the late-onset form has all her enzyme shortage ahead of her, not behind her. The screening program has given you the most valuable thing this condition allows: time, and the ability to act before damage rather than after. What her future looks like in practice: regular checks as she grows, measuring muscle strength, breathing, and heart, and enzyme replacement started when the team judges the moment right, guided by symptoms and measurements rather than the calendar. When it starts, it is an infusion every two weeks, and the evidence from children like her is that treatment stabilizes the condition for most and lets ordinary childhoods proceed. It is also worth saying plainly: this field is moving, with better enzymes and gene therapies in trials, and a child diagnosed today is growing up alongside improving treatment, not behind it. Get the genetic counseling for your family, let the specialist center build her monitoring schedule, and let her be a healthy newborn for now, because she is one.

Thanks for giving me all this information. A diagnosis delivered by a screening program, for a condition your daughter shows no sign of, is a surreal kind of news, and the disbelief in your question is completely reasonable. The frame to hold: she is healthy now, the condition is slow, and the screening has bought her the earliest possible start, which is the single biggest advantage Pompe allows. Your questions for the team: what exactly will you measure and how often, what would trigger starting the enzyme, and who handles our family's genetic counseling and testing. Welcome her home, love her as the ordinary newborn she is, and let the monitoring run quietly in the background of an ordinary childhood.

Care note

Parent consult, newborn screen positive, late-onset Pompe, baby currently healthy. The consult resolves the paradox of a healthy baby with a diagnosis by locating the disease entirely in her future, and frames screening as buying the earliest start. Treatment-when-triggered explained, and the moving-field note (better enzymes, gene therapy) is honest and age-relevant for a child with decades ahead.

Recessive inheritance with one in four sibling risk stated plainly. Infant vs late-onset split kept sharp because conflating them terrifies late-onset families with infant outcomes. Sources: MedlinePlus Genetics pompe-disease, NORD pompe-disease (charity page - flagged). No chains, banned adverbs absent.

View care note →

Illustrative example, not a real member's messages.

Common questions

How can my baby have a disease when she looks perfectly healthy?

Because late-onset Pompe works slowly over years. The enzyme shortage is present from birth, but glycogen accumulates gradually, and symptoms appear in childhood, adolescence, or adulthood. Screening found the condition long before it found her, which is the point of screening.

Is Pompe disease treatable?

Yes. Enzyme replacement therapy, the missing enzyme made in a lab and infused every two weeks, is the standard treatment. In the infant form it transformed survival; in the later form it stabilizes or slows the weakness for most people, especially when started early.

When will she need to start treatment?

Not on a fixed calendar. The team monitors her strength, breathing, and heart on a schedule, and starts the enzyme when measurements or symptoms say the time is right. Starting before major damage preserves the most function.

Did we give this to her? Could our other children have it?

Both parents each carry one silent copy of the changed gene, and neither knew. Each child has a one in four chance of the condition and a one in two chance of being a healthy carrier like you. Siblings should be tested, and genetic counseling maps the family clearly.

What should we watch for as she grows?

Falling behind on movement milestones, unusual clumsiness, breathing trouble, morning headaches or unrefreshing sleep, and slow growth. Her monitoring schedule is designed to catch all of these earlier than you can, but your eyes between visits are part of the system.

What is the long-term outlook for the late-onset form?

With monitoring and enzyme treatment, most people stabilize and live full lives, with weakness managed over decades rather than months. The field is advancing, with improved enzymes and gene therapies in trials, so a child diagnosed today grows up alongside better treatments, not behind them.

Sources

Pymander is not a replacement for a physician and does not provide medical advice, diagnosis, or treatment.